While the MUC1-based mRNA vaccine elicited an antigen-specific cytotoxic T-cell response and enhanced T-cell infiltration into the tumor, the combination with CTLA-4 siRNA appeared to enhance this effect. Here, MUC1 is linked to neoplasm.